| 1 |
Kang WH, Hwang S, Kaibori M, Kim JM, Kim KS, Kobayashi T, Kayashima H, Koh YS, Kubota K, Mori A, Takeda Y, Yun SS, Matsui K, Toriguchi K, Nagano H, Yoon MH, Soejima Y, Ariizumi S, Kim BS, Park Y, Yu HC, Kim BW, Lee JB, Park SJ, Jang JY, Yamaue H, Nakamura M, Yamamoto M, Endo I; Collaboration of Korean Association of Hepato-Biliary-Pancreatic Surgery, Japanese Society of Hepato-Biliary-Pancreatic Surgery. Validation of quantitative prognostic prediction using ADV score for resection of hepatocellular carcinoma: A Korea-Japan collaborative study with 9200 patients. J Hepatobiliary Pancreat Sci 2023. [PMID: 36808234 DOI: 10.1002/jhbp.1319] [Reference Citation Analysis]
|
| 2 |
Lee HA, Kim SU, Seo YS, Ahn SH, Rim CH. Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis. Hepatol Commun 2023;7:e0011. [PMID: 36691962 DOI: 10.1097/HC9.0000000000000011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Lee HA, Lee YS, Jung YK, Kim JH, Yim HJ, Yeon JE, Seo YS, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. The clinical effect of antiviral therapy in patients with hepatitis B virus-related decompensated cirrhosis and undetectable DNA. J Gastroenterol Hepatol 2023. [PMID: 36681856 DOI: 10.1111/jgh.16132] [Reference Citation Analysis]
|
| 4 |
Yim HJ, Jung YK, Ahn SH, Kim W, Yang JM, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Sohn JH, Lee JW, Park SJ, Yim SY, Park JK, Um SH. Reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B receiving long-term besifovir therapy.. [DOI: 10.21203/rs.3.rs-2442726/v1] [Reference Citation Analysis]
|
| 5 |
Hwang SY, Yoo SH, Chang HY, Kim S, Lee JI, Lee KS, Cho YY, Joon KH, Lee HW. Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals. J Viral Hepat 2023;30:39-45. [PMID: 36321949 DOI: 10.1111/jvh.13765] [Reference Citation Analysis]
|
| 6 |
Kong JH, Jang JY, Ko TH, Kang SH, Kim Y. High rate of hepatitis B reactivation during tyrosine kinase inhibitor treatment among patients with chronic myeloid leukemia in Korea. Blood Res 2022;57:290-3. [PMID: 36419239 DOI: 10.5045/br.2022.2022099] [Reference Citation Analysis]
|
| 7 |
Guo X, Ji T, Xin S, Xu J, Yu Y. A case report of hepatitis B virus reactivation 19 months after cessation of chemotherapy with rituximab. Front Immunol 2022;13:1083862. [PMID: 36532005 DOI: 10.3389/fimmu.2022.1083862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Oh JH, Park DA, Ko MJ, Yoo JJ, Yim SY, Ahn JH, Jun DW, Ahn SB. Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis. J Pers Med 2022;12. [PMID: 36556178 DOI: 10.3390/jpm12121957] [Reference Citation Analysis]
|
| 9 |
Lee JH, Shin SK, Kang SH, Kim TH, Yim HJ, Yim SY, Lee YS, Jung YK, Kim JH, Seo YS, Yeon JE, Kwon OS, Um SH, Byun KS. Long-Term Prediction Model for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Antiviral Therapy: Based on Data from Korean Patients. J Clin Med 2022;11. [PMID: 36431090 DOI: 10.3390/jcm11226613] [Reference Citation Analysis]
|
| 10 |
Lee HA, Kim SS, Choi JY, Seo YS, Park BJ, Sim KC, Kim SU. Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease. Abdom Radiol (NY) 2022;47:3733-45. [PMID: 35962809 DOI: 10.1007/s00261-022-03618-x] [Reference Citation Analysis]
|
| 11 |
Lin X, Zheng Y, Li H, Lu J, Ren S, Liu Y, Wang X, Zheng S, Ma L, Cao Z, Chen X. Serum hepatitis B virus large and medium surface proteins as novel tools for predicting HBsAg clearance. Front Immunol 2022;13:1028921. [DOI: 10.3389/fimmu.2022.1028921] [Reference Citation Analysis]
|
| 12 |
Yim HJ, Kim JH, Cho YK, Kweon YO, Cho HC, Hwang JS, Lee C, Koh MS, Baek Y, Park Y, Lee J, Kim SU, Kang M, Park NH, Lee JS, Chon YE, Cheon GJ, Chae HB, Sohn JH, Lim Y. Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients. DDDT 2022;Volume 16:3263-3274. [DOI: 10.2147/dddt.s376821] [Reference Citation Analysis]
|
| 13 |
Yang H, Bae SH, Nam H, Lee HL, Lee SW, Yoo SH, Song MJ, Kwon JH, Nam SW, Choi JY, Yoon SK, Jang JW. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol 2022;77:632-41. [PMID: 35398462 DOI: 10.1016/j.jhep.2022.03.032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 14 |
Chang JI, Sinn DH, Cho H, Kim S, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels. Dig Dis Sci 2022;67:4565-73. [PMID: 34800218 DOI: 10.1007/s10620-021-07312-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 15 |
Lim J, Lee JB, An J, Song GW, Kim KM, Lee HC, Shim JH. Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000-Korean outcome study. J Viral Hepat 2022;29:756-64. [PMID: 35718999 DOI: 10.1111/jvh.13721] [Reference Citation Analysis]
|
| 16 |
Shin SH, Park SH. Viral Hepatitis in Patients with Inflammatory Bowel Disease. Korean J Gastroenterol 2022;80:51-59. [DOI: 10.4166/kjg.2022.096] [Reference Citation Analysis]
|
| 17 |
Kim SK, Fujii T, Kim SR, Nakai A, Lim YS, Hagiwara S, Kudo M. Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus. Liver Cancer 2022;11:497-510. [PMID: 36589728 DOI: 10.1159/000525518] [Reference Citation Analysis]
|
| 18 |
Lim YS, Ahn SH, Shim JJ, Razavi H, Razavi-Shearer D, Sinn DH. Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis. Aliment Pharmacol Ther 2022;56:519-28. [PMID: 35614532 DOI: 10.1111/apt.17052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Jang H, Lee YB, Moon H, Chung JW, Nam JY, Cho EJ, Lee JH, Yu SJ, Kim YJ, Lee J, Yoon JH. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatology 2022;76:492-501. [PMID: 35100447 DOI: 10.1002/hep.32380] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 20 |
Lv Y, Song Q, Yue Z, Zhao H, Wang L, Fan Z, Wu Y, Meng M, Zhang K, Jiang L, Ding H, Zhang Y, Liu F. Correlation between hepatic venous pressure gradient and portal venous pressure gradient in hepatitis B cirrhosis with different hepatic veins anatomy. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110463] [Reference Citation Analysis]
|
| 21 |
Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma. Eur J Intern Med 2022:S0953-6205(22)00252-7. [PMID: 35835625 DOI: 10.1016/j.ejim.2022.07.003] [Reference Citation Analysis]
|
| 22 |
Won J, Lee AR, Dezhbord M, Lee DR, Kim SH, Kim JC, Park S, Kim N, Jae B, Kim K. Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir. Biomedicines 2022;10:1637. [DOI: 10.3390/biomedicines10071637] [Reference Citation Analysis]
|
| 23 |
Lin X, Song A, Lu J, Zheng S, Hu Z, Ma L, Cao Z, Li H, Zheng Y, Ren S, Chen X. Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure. Front Immunol 2022;13:879835. [DOI: 10.3389/fimmu.2022.879835] [Reference Citation Analysis]
|
| 24 |
Chun HS, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B. Dig Dis Sci 2022;67:3412-25. [PMID: 34476661 DOI: 10.1007/s10620-021-07157-1] [Reference Citation Analysis]
|
| 25 |
Lee HA, Chang Y, Sung PS, Yoon EL, Lee HW, Yoo JJ, Lee YS, An J, Song DS, Cho YY, Kim SU, Kim YJ. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. Clin Mol Hepatol 2022;28:425-72. [PMID: 35850495 DOI: 10.3350/cmh.2022.0186] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 26 |
Hong YM, Yoon KT. [Definition and Management of the Immune Tolerance Phase in Chronic Hepatitis B]. Korean J Gastroenterol 2022;79:156-60. [PMID: 35473773 DOI: 10.4166/kjg.2022.049] [Reference Citation Analysis]
|
| 27 |
Chon YE, Park SY, Kim SU, Hong HP, Lee JS, Lee HW, Kim MN, Park JY, Kim DY, Ahn SH, Kim BK. Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study. J Viral Hepat 2022;29:289-96. [PMID: 35152517 DOI: 10.1111/jvh.13656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 28 |
Lim YS, Seto WK, Kurosaki M, Fung S, Kao JH, Hou J, Gordon SC, Flaherty JF, Yee LJ, Zhao Y, Agarwal K, Lampertico P. Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther 2022;55:921-43. [PMID: 35178711 DOI: 10.1111/apt.16788] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 29 |
An J, Kim D, Oh B, Oh YJ, Song J, Park N, Kim HI, Kang HJ, Oh JH, Kim W, Lee E, Sung CO, Song GW, Kim DG, Yu E, Letouzé E, Zucman-Rossi J, Lee HC, Shim JH. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas. Hepatology 2022;75:997-1011. [PMID: 34478159 DOI: 10.1002/hep.32135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 30 |
Jung CY, Kim HW, Ahn SH, Kim SU, Kim BS. Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol 2022;20:956-958.e2. [PMID: 34029751 DOI: 10.1016/j.cgh.2021.05.032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 31 |
Choi NR, Kim JY, Hong JH, Hur MH, Cho H, Park MK, Kim J, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2022;22:135. [PMID: 35337274 DOI: 10.1186/s12876-022-02210-3] [Reference Citation Analysis]
|
| 32 |
Zhao Y, Kong LX, Feng FS, Yang J, Wei G. A simple CD4+ T cells to FIB-4 ratio for evaluating prognosis of BCLC-B hepatocellular carcinoma: a retrospective cohort study. BMC Cancer 2022;22:311. [PMID: 35321670 DOI: 10.1186/s12885-022-09433-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 33 |
Yim HJ, Kim W, Ahn SH, Jung YK, Um SH, Sohn JH, Jang JY, Kim DJ, Park ES, Jin SY, Kim KH. Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients. J Gastroenterol Hepatol 2022;37:378-86. [PMID: 34653281 DOI: 10.1111/jgh.15710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 34 |
Lee HW, Park SY, Lee YR, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL. Am J Gastroenterol 2022;117:288-94. [PMID: 34506308 DOI: 10.14309/ajg.0000000000001497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 35 |
Kim JC, Lee HY, Lee AR, Dezhbord M, Lee DR, Kim SH, Won J, Park S, Kim NY, Shin JJ, Kim SG, Kim YS, Yoo J, Kim K. Identification and Characterization of Besifovir-Resistant Hepatitis B Virus Isolated from a Chronic Hepatitis B Patient. Biomedicines 2022;10:282. [DOI: 10.3390/biomedicines10020282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 36 |
Sinn DH, Kang D, Guallar E, Hong YS, Cho J, Gwak GY. Modest alcohol intake and mortality in individuals with elevated alanine aminotransferase levels: a nationwide cohort study. BMC Med 2022;20:18. [PMID: 35067226 DOI: 10.1186/s12916-021-02215-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 37 |
Huang CF, Jang TY, Jun DW, Ahn SB, An J, Enomoto M, Takahashi H, Ogawa E, Yoon E, Jeong SW, Shim JJ, Jeong JY, Kim SE, Oh H, Kim HS, Cho YK, Kozuka R, Inoue K, Cheung KS, Mak LY, Huang JF, Dai CY, Yuen MF, Nguyen MH, Yu ML. On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. Liver Int 2022;42:59-68. [PMID: 34687130 DOI: 10.1111/liv.15085] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 38 |
Chon YE, Kim SU, Seo YS, Lee HW, Lee HA, Kim MN, Roh YH, Park JY, Kim DY, Ahn SH, Tak WY, Park SY, Kim BK. Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. J Gastroenterol Hepatol 2022;37:200-7. [PMID: 34478195 DOI: 10.1111/jgh.15678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 39 |
Kim S, Yoo S, Lee JI, Kim S, Chang HY, Kim D, Jeong SH, Lee KS, Lee HW. Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance. Dig Dis Sci 2022;67:321-8. [PMID: 33517556 DOI: 10.1007/s10620-021-06845-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 40 |
Goh MJ, Kang W, Kim KM, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. Scand J Gastroenterol 2022;57:70-7. [PMID: 34731072 DOI: 10.1080/00365521.2021.1988700] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 41 |
Zhong Z, Liao W, Dai L, Feng X, Su G, Gao Y, Wu Q, Yang P. Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection. Ann Rheum Dis 2021:annrheumdis-2021-221650. [PMID: 34933869 DOI: 10.1136/annrheumdis-2021-221650] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 42 |
Lee SW, Kim SM, Hur W, Kang BY, Lee HL, Nam H, Yoo SH, Sung PS, Kwon JH, Jang JW, Kim SJ, Yoon SK. Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway. PLoS One 2021;16:e0261067. [PMID: 34879114 DOI: 10.1371/journal.pone.0261067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 43 |
Lim J, Chon YE, Kim MN, Lee JH, Hwang SG, Lee HC, Ha Y. Cirrhosis, Age, and Liver Stiffness-Based Models Predict Hepatocellular Carcinoma in Asian Patients with Chronic Hepatitis B. Cancers (Basel) 2021;13:5609. [PMID: 34830764 DOI: 10.3390/cancers13225609] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 44 |
Kim HL, Kim GA, Park JA, Kang HR, Lee EK, Lim YS. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B. Gut 2021;70:2172-82. [PMID: 33239344 DOI: 10.1136/gutjnl-2020-321309] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 45 |
Wang X, Chen Y, Xu M, Cheng K, Duan X, Liao W, Wang Y, Lu Y, Duan Z, Wang L. Virologic response maintenance and hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir. Expert Rev Gastroenterol Hepatol 2021;15:1337-44. [PMID: 34511012 DOI: 10.1080/17474124.2021.1980385] [Reference Citation Analysis]
|
| 46 |
Jang Y, Ahn SH, Lee K, Kwon OY, Kim JH. Development and Pilot Testing of a Smartphone-Based Self-Care Program for Patients with Chronic Hepatitis B. Int J Environ Res Public Health 2021;18:11139. [PMID: 34769658 DOI: 10.3390/ijerph182111139] [Reference Citation Analysis]
|
| 47 |
Ju YC, Jun DW, Yoon EL, Ahn SB, Kim YJ, Nguyen MH. Nationwide Data on the Characteristics of Linked-to-Care Chronic Hepatitis B in Korea. J Clin Med 2021;10:4633. [PMID: 34682760 DOI: 10.3390/jcm10204633] [Reference Citation Analysis]
|
| 48 |
Lim JH, Yu JH, Suh YJ, Lee JW, Jin YJ. Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir. Medicine (Baltimore) 2021;100:e27417. [PMID: 34596169 DOI: 10.1097/MD.0000000000027417] [Reference Citation Analysis]
|
| 49 |
Kim JE, Sinn DH, Choi GS. Reply to "Emergent liver transplantation for patients with acute-on-chronic liver failure". Dig Liver Dis 2021;53:1361. [PMID: 34183283 DOI: 10.1016/j.dld.2021.05.023] [Reference Citation Analysis]
|
| 50 |
Yoo SH, Lim TS, Lee HW, Kim JK, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Lee JI, Lee KS, Kim SU. Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. J Viral Hepat 2021;28:1362-72. [PMID: 34185929 DOI: 10.1111/jvh.13560] [Reference Citation Analysis]
|
| 51 |
Jeong S, Cho Y, Park SM, Kim W. Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2021;55:e77-86. [PMID: 33883516 DOI: 10.1097/MCG.0000000000001548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 52 |
Na JE, Sinn DH, Lee JH, Jang HJ, Baek SY, Kim KA, Kang WS, Gwak GY, Paik YH, Kim YJ, Choi MS, Yoon JH, Lee JH, Koh KC, Paik SW. Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. J Viral Hepat 2021;28:1392-9. [PMID: 34251707 DOI: 10.1111/jvh.13572] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 53 |
Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 54 |
Lee SK, Sung PS, Park SS, Min CK, Nam H, Jang JW, Choi JY, Yoon SK. Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma. Clin Infect Dis 2021;73:e1372-5. [PMID: 33846712 DOI: 10.1093/cid/ciab302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 55 |
Kim KD, Lee JE, Kim JM, Lee O, Hwang NY, Rhu J, Choi GS, Kim K, Joh JW. Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea. Clin Mol Hepatol 2021;27:603-15. [PMID: 34492755 DOI: 10.3350/cmh.2021.0137] [Reference Citation Analysis]
|
| 56 |
Song JE, Park JY. Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B. Expert Opin Pharmacother 2021;:1-7. [PMID: 34392744 DOI: 10.1080/14656566.2021.1967321] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 57 |
Song DS, Jang JW, Yoo SH, Kwon JH, Nam SW, Bae SH, Choi JY, Yoon SK. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B. Clin Infect Dis 2021;73:e892-903. [PMID: 33417679 DOI: 10.1093/cid/ciab007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 58 |
Oh JH, Goh MJ, Park Y, Kim J, Kang W, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Paik YH. Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events. Dig Dis Sci 2021;66:2816-25. [PMID: 32897445 DOI: 10.1007/s10620-020-06591-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 59 |
Garbuzenko DV. Diagnostic and risk stratification aspects of liver fibrosis progression in chronic hepatitis B and C viral infection. Medical Journal of the Russian Federation 2021;27:373-384. [DOI: 10.17816/0869-2106-2021-27-4-373-384] [Reference Citation Analysis]
|
| 60 |
Chun HS, Park S, Lee M, Cho Y, Kim HS, Choe AR, Kim HY, Yoo K, Kim TH. Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. Cancers (Basel) 2021;13:3424. [PMID: 34298640 DOI: 10.3390/cancers13143424] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 61 |
Cho HJ, Baek GO, Yoon MG, Ahn HR, Son JA, Kim SS, Cheong JY, Eun JW. Overexpressed Proteins in HCC Cell-Derived Exosomes, CCT8, and Cofilin-1 Are Potential Biomarkers for Patients with HCC. Diagnostics (Basel) 2021;11:1221. [PMID: 34359304 DOI: 10.3390/diagnostics11071221] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 62 |
Ahn SB, Choi J, Jun DW, Oh H, Yoon EL, Kim HS, Jeong SW, Kim SE, Shim JJ, Cho YK, Lee HY, Han SW, Nguyen MH; SAINT cohort. Twelve-month post-treatment parameters are superior in predicting hepatocellular carcinoma in patients with chronic hepatitis B. Liver Int 2021;41:1652-61. [PMID: 33550661 DOI: 10.1111/liv.14820] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 63 |
Lee SW, Choi J, Kim SU, Lim YS. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol 2021;27:402-12. [PMID: 34157830 DOI: 10.3350/cmh.2021.0179] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 64 |
Chun HS, Lee M. Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status? Clin Mol Hepatol 2021;27:448-50. [PMID: 34157831 DOI: 10.3350/cmh.2021.0130] [Reference Citation Analysis]
|
| 65 |
Ji JH, Park SY, Son WJ, Shin HJ, Lee H, Lee HW, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. External validation of CAGE-B and SAGE-B scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals. J Viral Hepat 2021;28:951-8. [PMID: 33763928 DOI: 10.1111/jvh.13506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 66 |
Lee YB, Moon H, Lee JH, Cho EJ, Yu SJ, Kim YJ, Zoulim F, Lee J, Yoon JH. Association of Metabolic Risk Factors With Risks of Cancer and All-Cause Mortality in Patients With Chronic Hepatitis B. Hepatology 2021;73:2266-77. [PMID: 33140415 DOI: 10.1002/hep.31612] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 67 |
Lee YS, Bang SM, Lee YS. Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B. J Clin Med 2021;10:2320. [PMID: 34073357 DOI: 10.3390/jcm10112320] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 68 |
Lee HW, Lee HW, Lee JS, Roh YH, Lee H, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. J Hepatocell Carcinoma 2021;8:467-76. [PMID: 34079776 DOI: 10.2147/JHC.S300382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 69 |
Lee HW, Kim EH, Lee J, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. Clin Transl Gastroenterol 2020;11:e00140. [PMID: 32352711 DOI: 10.14309/ctg.0000000000000140] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 70 |
Ahn YH, Lee H, Kim DY, Lee HW, Yu SJ, Cho YY, Jang JW, Jang BK, Kim CW, Kim HY, Park H, Cho HJ, Park B, Kim SS, Cheong JY. Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C. Gut Liver 2021;15:410-9. [PMID: 32893194 DOI: 10.5009/gnl20151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 71 |
Kim M, Lee Y, Yoon JS, Lee M, Kye SS, Kim SW, Cho Y. The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. Cancers (Basel) 2021;13:2301. [PMID: 34064988 DOI: 10.3390/cancers13102301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 72 |
Abaalkhail FA, Al-Hamoudi WK, Khathlan A, Alghamdi S, Alghamdi M, Alqahtani SA, Sanai FM. SASLT practice guidelines for the management of Hepatitis B virus - An update. Saudi J Gastroenterol 2021;27:115-26. [PMID: 33976009 DOI: 10.4103/sjg.sjg_539_20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 73 |
Tsai YF, Hsu CM, Hsiao HH. Management of Hepatitis B Virus Reactivation in Malignant Lymphoma Prior to Immunosuppressive Treatment. J Pers Med 2021;11:267. [PMID: 33918206 DOI: 10.3390/jpm11040267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 74 |
Lee JH, Kim BK, Park SY, Tak WY, Park JY, Kim DY, Ahn SH, Sinn DH, Kim SU. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. Eur J Intern Med 2021;89:48-55. [PMID: 33810942 DOI: 10.1016/j.ejim.2021.02.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 75 |
Lee H, Kim BK, Jang S, Ahn SH. Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression. Clin Transl Gastroenterol 2021;12:e00299. [PMID: 33600103 DOI: 10.14309/ctg.0000000000000299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 76 |
Choi J, Jo C, Lim YS. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. Hepatology 2021;73:661-73. [PMID: 32324905 DOI: 10.1002/hep.31289] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 23.0] [Reference Citation Analysis]
|
| 77 |
Lee SK, Kwon JH, Lee SW, Jang JW, Nam H, Baik KW, Yoo SH, Nam SW, Sung PS, Bae SH, Choi JY, Yoon SK. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B. Liver Int 2021;41:288-94. [PMID: 33043567 DOI: 10.1111/liv.14701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 78 |
Yip TC, Wong GL, Wong VW. Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact. Clin Mol Hepatol 2021;27:273-7. [PMID: 33517606 DOI: 10.3350/cmh.2021.0019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 79 |
Choi J, Lim YS. Secondary prevention of hepatitis B virus-related hepatocellular carcinoma with current antiviral therapies. Kaohsiung J Med Sci 2021;37:262-7. [PMID: 33502828 DOI: 10.1002/kjm2.12364] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 80 |
Song DS, Kim W, Ahn SH, Yim HJ, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Yang JM, Kim KH, Han KH, Um SH. Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. Clin Mol Hepatol 2021;27:346-59. [PMID: 33493393 DOI: 10.3350/cmh.2020.0307] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 81 |
Ahn YE, Suh SJ, Kim TH, Jung YK, Yim HJ. Maintaining Antiviral Efficacy after Switching to Generic Entecavir 1 mg for Antiviral-resistant Chronic Hepatitis B. Korean J Gastroenterol 2021;77:22-9. [PMID: 33372170 DOI: 10.4166/kjg.2020.0144] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 82 |
Su TH, Kao JH. Withdrawal of Nucleos(t)ide Analogues in Hepatitis B e Antigen-Negative Patients: An Asian Perspective. Clin Liver Dis (Hoboken) 2020;16:244-8. [PMID: 33489096 DOI: 10.1002/cld.950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 83 |
Park Y, Lee JH, Sinn DH, Park JY, Kim MA, Kim YJ, Yoon JH, Kim DY, Ahn SH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. Clin Transl Gastroenterol 2021;12:e00290. [PMID: 33433118 DOI: 10.14309/ctg.0000000000000290] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 84 |
Kang B, Yi DY, Choe BH. Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries. Front Pediatr 2021;9:809838. [PMID: 35186829 DOI: 10.3389/fped.2021.809838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 85 |
Kim BH, Park J. Antiviral Therapy in Liver Cancer. Radiotherapy of Liver Cancer 2021. [DOI: 10.1007/978-981-16-1815-4_5] [Reference Citation Analysis]
|
| 86 |
Dulek DE, Fuhlbrigge RC, Tribble AC, Connelly JA, Loi MM, El Chebib H, Chandrakasan S, Otto WR, Diorio C, Keim G, Walkovich K, Jaggi P, Girotto JE, Yarbrough A, Behrens EM, Cron RQ, Bassiri H. Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients. J Pediatric Infect Dis Soc 2020;9:716-37. [PMID: 32808988 DOI: 10.1093/jpids/piaa098] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 87 |
Lee JH. Old hepatitis B virus never dies: It just hides itself within the host genome. Clin Mol Hepatol 2021;27:107-9. [PMID: 33353287 DOI: 10.3350/cmh.2020.0324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 88 |
Han S, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Han DH, Kim BK. Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. J Hepatocell Carcinoma 2020;7:403-12. [PMID: 33365287 DOI: 10.2147/JHC.S276528] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 89 |
Lee HW, Chon YE, Kim BK, Yip TC, Tse YK, Wong GL, Wong VW, Chan HL, Ahn SH. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. Eur J Intern Med 2021;84:68-73. [PMID: 33288393 DOI: 10.1016/j.ejim.2020.10.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 90 |
Kim SU, Chon YE, Seo YS, Lee HW, Lee HA, Kim MN, Min IK, Park JY, Kim DY, Ahn SH, Tak WY, Kim BK, Park SY. A multi-centre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy. J Viral Hepat 2020;27:1352-8. [PMID: 32852880 DOI: 10.1111/jvh.13384] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 91 |
Chon YE, Jung KS, Ha Y, Kim MN, Lee JH, Hwang SG, Ahn SH, Kim DY, Han KH, Park JY. High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis. J Viral Hepat 2020;27:1119-26. [PMID: 32558181 DOI: 10.1111/jvh.13345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 92 |
Kim KH, Joo DJ, Lee YH, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Association between liver fibrosis and appendicular skeletal muscle mass during antiviral therapy in chronic hepatitis B. Dig Liver Dis 2020;52:1338-45. [PMID: 32771386 DOI: 10.1016/j.dld.2020.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 93 |
Yoon JS, Lee HY, Chung SW, Kim SW, Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim H, Yoon JH, Kim YJ. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:1960-8. [PMID: 32128882 DOI: 10.1111/jgh.15026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 94 |
Lim TS, Lee HW, Lee JI, Kim IH, Lee CH, Jang BK, Chung WJ, Yim HJ, Suh SJ, Seo YS, Lee HA, Yu JH, Lee JW, Kim SG, Kim YS, Park SY, Tak WY, Kim SS, Cheong JY, Jeong SW, Jang JY, Rou WS, Lee BS, Kim SU; Korean Transient Elastography Study Group. Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir. J Viral Hepat 2020;27:1052-60. [PMID: 32383246 DOI: 10.1111/jvh.13316] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 95 |
Jeon MY, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Han KH, Ahn SH, Kim SU. Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma. J Viral Hepat 2020;27:932-40. [PMID: 32365240 DOI: 10.1111/jvh.13313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 96 |
Seo CG, Yim SY, Um SH, Lee YR, Lee YJ, Kim TH, Goh HG, Lee YS, Suh SJ, Han NY, Choi HS, Kim ES, Keum B, Seo YS, Yim HJ, Kim JH, Kim DS, Jeen YT, Chun HJ, Lee HS, Kim CD. Survival according to recurrence patterns after resection for transplantable hepatocellular carcinoma in HBV endemic area: Appraisal of liver transplantation strategy. Clin Res Hepatol Gastroenterol 2020;44:532-42. [PMID: 31870653 DOI: 10.1016/j.clinre.2019.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 97 |
Yoon EL, Oh H, Jun DW, Nguyen MH. Editorial: comorbidities in patients with chronic hepatitis B-authors' reply. Aliment Pharmacol Ther 2020;52:893-4. [PMID: 32852828 DOI: 10.1111/apt.15979] [Reference Citation Analysis]
|
| 98 |
Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411-429. [PMID: 32854458 DOI: 10.3350/cmh.2020.0049] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 99 |
Fang Z, Yu X, Tong S, Lu C, Huang Y, Chen L, Yuan Z, Zhang Y. Serum ERK1/2 proteins fluctuating with HBV infection report frequency of viral-specific CD8+ T cells and predict IFNα therapeutic effect in chronic hepatitis B patients. Clin Immunol 2020;219:108570. [PMID: 32791312 DOI: 10.1016/j.clim.2020.108570] [Reference Citation Analysis]
|
| 100 |
Yim HJ, Kim W, Ahn SH, Yang JM, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Um SH, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Han KH. Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial. Am J Gastroenterol 2020;115:1217-25. [PMID: 32355123 DOI: 10.14309/ajg.0000000000000605] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 101 |
Lee HW, Park SY, Lee M, Lee EJ, Lee J, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. Liver Int 2020;40:1736-43. [PMID: 32239602 DOI: 10.1111/liv.14451] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 102 |
Lim TS, Kim JK. Is liver biopsy still useful in the era of non-invasive tests? Clin Mol Hepatol 2020;26:302-4. [PMID: 32646204 DOI: 10.3350/cmh.2020.0081] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 103 |
Jang BK. Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? Clin Mol Hepatol 2020;26:312-4. [PMID: 32646206 DOI: 10.3350/cmh.2020.0099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 104 |
Kim J, Chung SJ, Sinn DH, Lee KW, Park JB, Huh W, Lee JE, Jang HR, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients. J Viral Hepat 2020;27:739-46. [PMID: 32057171 DOI: 10.1111/jvh.13279] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 105 |
Lee HA, Lee HW, Kim IH, Park SY, Sinn DH, Yu JH, Seo YS, Um SH, Lee JI, Lee KS, Lee CH, Tak WY, Kweon YO, Kang W, Paik YH, Lee JW, Suh SJ, Jung YK, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yim HJ, Kim SU. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther 2020;52:196-204. [PMID: 32452564 DOI: 10.1111/apt.15741] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 106 |
Lyubchak VV, Plaksa VM, Pelo IM, Kovalishyn MP, Lyubchak VP, Horokh VV, Lisovenko TI, Ilyina VV, Khomenko LM. THERAPEUTIC PLASMAPHERESIS IN A COMPLEX TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS. Wiad Lek 2020;73:1454-1458. [DOI: 10.36740/wlek202007126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 107 |
Kim JH, Sinn DH. Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change? Clin Mol Hepatol 2020;26:315-7. [PMID: 32570301 DOI: 10.3350/cmh.2020.0084] [Reference Citation Analysis]
|
| 108 |
Kim GA, Han S, Choi GH, Choi J, Lim YS. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther 2020;51:1169-79. [PMID: 32291781 DOI: 10.1111/apt.15725] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 109 |
Kim GA, Lim YS. Editorial: hepatitis B DNA thresholds and risk of hepatocellular carcinoma: different number patterns in HBeAg-positive versus HBeAg-negative patients. Authors' reply. Aliment Pharmacol Ther 2020;51:1440-1. [PMID: 32445524 DOI: 10.1111/apt.15794] [Reference Citation Analysis]
|
| 110 |
Sinn DH. [Natural History and Treatment Indications of Chronic Hepatitis B]. Korean J Gastroenterol 2019;74:245-50. [PMID: 31765552 DOI: 10.4166/kjg.2019.74.5.245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 111 |
Lee HW. [Long Term Efficacy of Antiviral Therapy: Mortality and Incidence of Hepatocellular Carcinoma]. Korean J Gastroenterol 2019;74:251-7. [PMID: 31765553 DOI: 10.4166/kjg.2019.74.5.251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 112 |
Yoo SH, Kwon JH. [New Potential Therapies for Chronic Hepatitis B]. Korean J Gastroenterol 2019;74:267-73. [PMID: 31765555 DOI: 10.4166/kjg.2019.74.5.267] [Reference Citation Analysis]
|
| 113 |
Yoon EL. [Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients]. Korean J Gastroenterol 2019;74:258-66. [PMID: 31765554 DOI: 10.4166/kjg.2019.74.5.258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 114 |
Jung YW, Kim M, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B. J Korean Med Sci 2020;35:e104. [PMID: 32356416 DOI: 10.3346/jkms.2020.35.e104] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 115 |
Lee HW, Lee JI, Kim S, Kim S, Chang HY, Lee KS. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance. BMC Gastroenterol 2020;20:113. [PMID: 32305059 DOI: 10.1186/s12876-020-01236-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 116 |
Hadziyannis E, Hadziyannis S. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2020;14:243-51. [PMID: 32162562 DOI: 10.1080/17474124.2020.1738219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 117 |
Kim SU, Seo YS, Lee HA, Kim MN, Kim EH, Kim HY, Lee YR, Lee HW, Park JY, Kim DY, Ahn SH, Han KH, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Kim BK, Park SY. Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. Clin Gastroenterol Hepatol 2020;18:693-699.e1. [PMID: 31252188 DOI: 10.1016/j.cgh.2019.06.028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 118 |
Park SK, Choi CH, Chun J, Lee H, Kim ES, Park JJ, Park CH, Lee BI, Jung Y, Park DI, Kim DY, Park H, Jeen YT; IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest Res. 2020;18:18-33. [PMID: 32013312 DOI: 10.5217/ir.2019.09155] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 119 |
Cho HJ, Eun JW, Baek GO, Seo CW, Ahn HR, Kim SS, Cho SW, Cheong JY. Serum Exosomal MicroRNA, miR-10b-5p, as a Potential Diagnostic Biomarker for Early-Stage Hepatocellular Carcinoma. J Clin Med 2020;9:E281. [PMID: 31968558 DOI: 10.3390/jcm9010281] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 120 |
Kim BK. Reply to: "Comment on - A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea". J Hepatol 2020;72:198-9. [PMID: 31727342 DOI: 10.1016/j.jhep.2019.10.012] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 121 |
Chang JH. Kidney disease in patients with chronic liver disease. J Korean Med Assoc 2020;63:14. [DOI: 10.5124/jkma.2020.63.1.14] [Reference Citation Analysis]
|
| 122 |
Kim BK. Reply to: "Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction". J Hepatol 2019;71:847-8. [PMID: 31383378 DOI: 10.1016/j.jhep.2019.07.004] [Reference Citation Analysis]
|
